Agena Bioscience, Inc.. (10/05/17). "Press Release: Agena Bioscience Bolsters MassARRAY Insights Reporting Network by Adding N-of-One". San Diego, CA.

	Organisation	Agena Bioscience Inc.
	Group	Agena Bioscience (Group)
	Organisation 2	N-of-One Inc.
	Group	Qiagen (Group)
	Product	MassARRAY® system
	Product 2	genomic software tools
	Person	Dansky, Peter M. (Agena Bioscience 201407– CEO before Life Technologies + Applied Biosystems + Arcturus + Affymetrix)

The collaboration will focus on results interpretation for cancer genomics.

Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY® System.

This strategic partnership supports the expansion of Agena’s recently launched MassARRAY Insights reporting network, which connects the unique capabilities of the MassARRAY with the power of high quality analysis to aid in results interpretation. N-of-One’s long standing expertise in clinical interpretation of molecular tests in oncology aids CLIA High Complexity Labs in rapidly delivering actionable, patient-specific treatment options that are supported by the latest scientific and clinical evidence.

“MassARRAY Insights is part of Agena Bioscience’s continued effort to support our CLIA-High Complexity Certified lab customers who are tackling the challenges presented in molecular diagnostics. We are happy to partner with an industry leader like N-of-One to help bring our lab clients an important component that nicely follows the value of our test: an evidence-based, clinically actionable report,” said Pete Dansky, Chief Executive Officer at Agena Bioscience.

“With technology like Agena’s MassARRAY, clinicians have the ability to develop tests that provide robust data. With our data interpretation expertise, we can guide pathologists and oncologists to more precise and tailored cancer treatments than ever before. At N-of-One, we are happy to partner with Agena Bioscience, as we are aligned in tackling complex molecular data and helping to make sense of it for the clinician,” said Chris Cournoyer, Chief Executive Officer at N-of-One, Inc.

Agena’s MassARRAY System is intended for Research Use Only. Not for use in diagnostic procedures.

MassARRAY Insights reporting networks can be found at www.agenabio.com/services/insights

About Agena Bioscience

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

About N-of-One

N-of-One is a leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call +1 617-202-9808.

Media Contact:

Agena Bioscience
Mickie Henshall
(858) 882-2707
mickie.henshall@agenabio.com

N-of-One Media Relations Contact:
Lisa Rivero
Lisa.Rivero@fkhealth.com

Record changed: 2023-06-05